跳转至内容
Merck
CN

SML2156

埃罗替尼 盐酸盐

≥98% (HPLC), EGFR kinase inhibitor, powder

别名:

774 盐酸盐, CP-358, N-(3-乙炔基苯基)-6,7-双(2-甲氧基乙氧基)喹唑啉-4-胺, OSI-744 盐酸盐

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C22H23N3O4 · HCl
化学文摘社编号:
分子量:
429.90
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

埃罗替尼 盐酸盐, ≥98% (HPLC)

SMILES string

Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI

1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

InChI key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

General description

盐酸厄洛替尼是一种抗肿瘤药物。它调节雷帕霉素(mTOR)抑制的机制靶点、表皮生长因子受体下调和表皮间质转化(EMT)抑制。

Application

盐酸厄洛替尼已被用于激活人 PANC-1 胰腺癌细胞系中的线粒体片段化。

Biochem/physiol Actions

EGFR 激酶抑制剂;抗肿瘤
盐酸埃罗替尼是受体酪氨酸激酶 EGFR(表皮生长因子受体)的抑制剂。它在临床上用于治疗非小细胞肺癌(NSCLC)和联合治疗转移性胰腺癌。

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)
Kandasamy Saravanakumar et al.
Carbohydrate polymers, 245, 116407-116407 (2020-07-29)
The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95
J D Moyer et al.
Cancer research, 57(21), 4838-4848 (1997-11-14)
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR
Rabea Oberthür et al.
Cancer letters, 407, 93-105 (2017-08-22)
Overexpression and activation of receptor tyrosine kinases (RTKs), such as the insulin-like growth factor 1 receptor (IGF1R) and the epidermal growth factor receptor (EGFR), are frequent phenomena in colorectal cancer (CRC). Here, we evaluated the effect and the cellular mechanisms
Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways
Wan J, et al.
Cancer Cell International, 18(1), 165-165 (2018)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持